Marc Hofmann, MD
Pulmonary Disease · Gallatin, TNNPI 1861498313
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 62.4% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $23,057 and has fallen 93.9% since, to $1,418 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $79.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$31K
- Axsome Therapeutics, Inc.$9K
- GSK$2K
- Harmony Biosciences LLC$2K
- AstraZeneca$992
- Avadel CNS Pharmaceuticals, LLC$414
- plus $4K from 41 others
Across 1 payment — averaging $8142.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Respicardia, Inc.$8K
What the payments were for
- Consulting fees$8,07516%
- Speaking & faculty fees$24,65050%
- Travel & lodging$2,1494%
- Food & beverage$13,35227%
- Education$8812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,107 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 37 | $629,568 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 237 | $233,280 |
| WakixPitolisant Hcl | 13 | $179,340 |
| OpsumitMacitentan | 12 | $153,841 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $26,972 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $13,491 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,590 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $6,268 |
| Modafinil | 62 | $5,493 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,788 |
| Doxepin Hcl | 14 | $2,786 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $2,374 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $1,658 |
| Methylphenidate Hcl | 19 | $995 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $2,220 | $246,771260 claims |
| Harmony Biosciences LLCWakix | $1,672 | $179,34013 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $413 | $153,84112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $992 | $33,56348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Gallatin
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
- John SwisherKnoxville$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.